Phycocyanin Cancer Research Results

Phyco, Phycocyanin: Click to Expand ⟱
Features:

Phycocyanin — a water-soluble blue phycobiliprotein/chromoprotein found in cyanobacteria and red algae, best characterized as C-phycocyanin from Arthrospira platensis (Spirulina). It consists of α- and β-protein subunits carrying the linear tetrapyrrole chromophore phycocyanobilin. It is formally a natural-product biliprotein and food-derived bioactive rather than a conventional small-molecule drug. Standard abbreviations are PC and C-PC. Phycocyanin should be added as a separate Nestronics product because it is a chemically and functionally defined major bioactive component of Spirulina, has a substantial independent cancer literature, and is also being investigated as a photosensitizer, sonosensitizer, drug carrier, radiosensitizer, and therapeutic protein. It should not be treated as synonymous with whole Spirulina biomass.

Primary mechanisms (ranked):

  1. Induction of intrinsic and extrinsic apoptosis, including ↓ Bcl-2, ↑ Bax, mitochondrial membrane depolarization, cytochrome-c release and activation of caspases 3, 8 and 9.
  2. Suppression of proliferative and survival signaling, particularly COX-2/PGE2, MAPK/ERK, PI3K/Akt/mTOR and context-dependent NF-κB signaling.
  3. Cell-cycle arrest through modulation of cyclins, CDKs, p21 and p27, with G0/G1, S or G2/M arrest depending on tumor model.
  4. Induction of autophagic cell death in selected cancers through inhibition of PI3K/Akt/mTOR signaling and interaction between autophagy and apoptosis pathways.
  5. Inhibition of migration, invasion, angiogenesis and metastatic phenotypes, including effects on MAPK, COX-2/PGE2 and related signaling.
  6. Redox modulation: C-PC is generally antioxidant in normal biological systems but can produce ↑ ROS, mitochondrial oxidative stress and GSH depletion in some cancer models; strong ROS generation also occurs when C-PC is used as a photo- or sonosensitizer.
  7. Radiosensitization and chemosensitization reported preclinically, including enhancement of radiation, topotecan, cisplatin and taxane-based approaches.

Bioavailability / PK relevance: Native C-PC is a relatively large protein complex and is unstable to heat, acidic pH and gastrointestinal proteolysis. Oral intact-protein systemic bioavailability is therefore expected to be low, and digestion produces phycocyanin-derived peptides and phycocyanobilin with potentially different pharmacology. Encapsulation, nanoparticles, PEGylation and colon-targeted formulations are being investigated specifically because poor stability and delivery limit translation. Food-grade phycocyanin-rich preparations can nevertheless be consumed orally, and approximately 1 g/day phycocyanin-equivalent exposure was used for two weeks in a small human safety RCT.

In-vitro vs systemic exposure relevance: Many anticancer experiments expose cells directly to approximately tens to hundreds of µg/mL C-PC, with some studies using still higher concentrations. These exposures should not be assumed achievable as intact circulating C-PC after ordinary oral supplementation because gastrointestinal degradation and uncertain systemic absorption substantially separate oral exposure from direct cell-culture exposure. Photodynamic and sonodynamic applications are additionally trigger-dependent and should be evaluated separately from unactivated oral C-PC.

Clinical evidence status: Preclinical for cancer treatment. Evidence includes numerous cancer-cell studies and several animal tumor models, but there is no established anticancer indication or validated therapeutic cancer dose in humans. Human exposure data mainly concern food/supplement safety rather than cancer efficacy. A small randomized safety study found a phycocyanin-rich extract providing approximately 1 g/day phycocyanin for two weeks to be well tolerated, but this does not establish anticancer efficacy. Rare IgE-mediated allergy and anaphylaxis to Spirulina/phycocyanin have been documented. Regulatory acceptance of Spirulina/phycocyanin-rich extracts as food ingredients or color additives should not be interpreted as approval of phycocyanin as a cancer drug.

Phycocyanin Cancer Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells Primary Effect Notes / Interpretation
1 Mitochondrial apoptosis ↑ Bax/Bcl-2 ratio; ↓ mitochondrial membrane potential; ↑ cytochrome c; ↑ caspase-9 and caspase-3 Generally less cytotoxic in tested normal-cell models Apoptotic cell death One of the most reproducible anticancer effects across leukemia, breast, cervical, prostate and other models.
2 COX-2 and PGE2 ↓ COX-2; ↓ PGE2 ↓ inflammatory COX-2 activity (context-dependent) ↓ proliferation, inflammation and tumor-supportive signaling C-PC has been described as a selective COX-2 inhibitor. COX-2 suppression is also implicated in radiosensitization and antimetastatic effects.
3 PI3K Akt mTOR and autophagy ↓ PI3K/Akt/mTOR; ↑ autophagy (model-dependent) Context-dependent Growth inhibition and autophagic cell death Especially well characterized in pancreatic cancer, where autophagy and apoptosis cooperate in C-PC-mediated cytotoxicity.
4 MAPK survival signaling ↓ ERK; ↑ p38/JNK or broader MAPK remodeling (model-dependent) Context-dependent ↓ proliferation; ↑ apoptosis; ↓ migration Direction varies by cancer model. Breast and pancreatic cancer studies support substantial MAPK involvement.
5 NF-κB survival and inflammatory signaling Usually ↓ NF-κB pathway activity; occasionally ↑ NF-κB during autophagy/apoptosis balancing (model-dependent) Often ↓ inflammatory NF-κB signaling ↓ proliferation and survival signaling RIPK1/NF-κB and TIRAP/NF-κB suppression has been demonstrated in NSCLC. NF-κB responses are not uniformly unidirectional across tumor systems.
6 Cell-cycle control ↓ Cyclin D1/CDK activity; ↑ p21/p27; ↑ G0/G1, S or G2/M arrest (model-dependent) Less pronounced in available comparative models ↓ proliferation The arrest phase varies substantially with cell type and exposure conditions.
7 ROS and mitochondrial oxidative stress ↑ ROS; ↓ GSH; ↓ mitochondrial function in selected models (dose-dependent) Often ↓ oxidative stress and radical burden Selective redox stress and apoptosis Important apparent dichotomy: C-PC is broadly antioxidant yet can become pro-oxidant in some cancer cells. ROS generation becomes much stronger with external photodynamic or sonodynamic activation.
8 Migration invasion and angiogenesis ↓ migration; ↓ invasion; ↓ angiogenic phenotype Limited evidence of harmful suppression at comparable exposures ↓ metastatic potential Reported in triple-negative breast cancer, NSCLC and other models; mechanisms overlap MAPK and COX-2/PGE2 signaling.
9 Radiosensitization ↑ radiation response; ↓ clonogenic survival Relative sparing reported in tested normal colon cells ↑ radiation cytotoxicity Preclinical colon-cancer work links the effect partly to ↓ COX-2. No established human radiosensitizer role.
10 Chemosensitization ↑ response to topotecan, cisplatin and other agents (model-dependent) Potential reduction of required cytotoxic exposure remains unproven clinically Enhanced combination therapy Combination studies are preclinical. Mechanisms include ↑ ROS, caspase activation and altered drug-resistance pathways.
11 Photo and sonodynamic activation ↑ ROS (requires external trigger); ↓ mitochondrial membrane potential; ↑ apoptosis Depends strongly on localization and trigger geometry Triggered oxidative cytotoxicity C-PC can function as a photosensitizer and sonosensitizer. These applications should be distinguished from unactivated C-PC pharmacology.
12 Clinical Translation Constraint Direct in-vitro exposure frequently exceeds plausible intact systemic exposure after oral dosing Food exposure is generally tolerated, but rare allergy including anaphylaxis is documented Limits translation from cell culture to oral cancer therapy Poor gastrointestinal stability, proteolysis, formulation dependence, heterogeneous preparations and absence of cancer efficacy trials are major constraints. Nanocarriers and protected delivery formulations may materially change exposure.


Scientific Papers found: Click to Expand⟱
9022- Phyco,  TPT,    Phycocyanin induces apoptosis and enhances the effect of topotecan on prostate cell line LNCaP
- in-vitro, Pca, LNCaP
Synergy↑, ROS↑, Casp3↑, Casp9↑, Dose↝,
9032- Phyco,    C-phycocyanin, a very potent and novel platelet aggregation inhibitor from Spirulina platensis
- in-vitro, Nor, NA
*AntiAg↑, *TXA2↓, *other↑, *eff↑,
9031- Phyco,    C-Phycocyanin induces apoptosis in oral squamous cell carcinoma KB cells via modulation of key molecular pathways
- in-vitro, Oral, NA
tumCV↓, selectivity↑, DNAdam↑, ChrCon↑, Apoptosis↑, P53↑, Bcl-2↓, Akt↓, PTEN↑, ERK↑,
9030- Phyco,    Enhancing the gastrointestinal stability of phycocyanin through modified PEGylation: Prospects for oral anticancer treatment
- in-vitro, Oral, NA
BioAv↓, Synergy↑, BioAv↑, tumCV↓, ROS↑, mtDam↑,
9029- Phyco,    Advances about the study of phycocyanin in the treatment of breast cancer: A review
- Review, BC, NA
*antiOx↓, *Inflam↓, AntiTum↑, Apoptosis↑, ROS↑, mtDam?, TumCCA↑, TumCP↓, Tumccf↓, *toxicity↓, TumCG↓, EMT↓, COX2/PTGS2↓,
9028- Phyco,    Enhancing the bioavailability and stability of phycocyanin loaded into double-layered pectin-chitosan nanocarriers
- Study, Nor, NA
BioAv↑, Ingr↝,
9027- Phyco,  5-FU,    C-Phycocyanin-Cisplatin Combination Targeting Redox Balance for Enhanced Efficacy Against Glioblastoma Cells
- in-vivo, GBM, U87MG
tumCV↓, selectivity↑, ChemoSen↑, Apoptosis↑, DNAdam↑, cl‑Casp3↑, cl‑PARP↑, ROS↓, SOD2↑, Catalase↑,
9026- Phyco,    Phycocyanin oral delivery system obtained by spray-drying with soy proteins for the treatment of inflammatory bowel diseases: in vivo evaluation
- in-vivo, IBD, NA
*BioAv↑, *Ingr↝, *Inflam↓, *MPO↓, *IL6↓,
9025- Phyco,    Clinical Safety of a High Dose of Phycocyanin-Enriched Aqueous Extract from Arthrospira (Spirulina) platensis: Results from a Randomized, Double-Blind, Placebo-Controlled Study with a Focus on Anticoagulant Activity and Platelet Activation
- Trial, Nor, NA
*Dose↝, *AST↓, *ALAT↓, *Pain↓, *hepatoP↑,
9024- Phyco,    pH-activated liquid microdroplet carrier for enhanced phycocyanin oral delivery and sustained bioactivity post-digestion
- Study, Nor, NA
*BioAv↓, *BioAv↑,
9023- Phyco,  PDT,    In Vitro Photodynamic Effect of Phycocyanin against Breast Cancer Cells
- in-vitro, BC, MDA-MB-231
Synergy↑, ROS↑, TumCD↑, *toxicity↓, hepatoP↑, Dose↝, MMP↓, BAX↑, Bak↑, Cyt‑c↑,
9011- Phyco,    Phycocyanin: A Potential Drug for Cancer Treatment
- Review, Var, NA
*antiOx↑, *Inflam↓, *AntiCan↑, *Imm↑, *RenoP↑, *hepatoP↑, Synergy↑, EMT↓, TumCCA↑, P21↑, cycE/CCNE↓, CDK2↓, Cyt‑c↑, Casp↑, cl‑PARP1↑, Bax:Bcl2↑, MMP↓, ROS↑, CD59↑, Fas?, IL1β↓, IL2↓, IFN-γ↓, TNF-α↓, JAK3↓, STAT3↓, IL4↑, COX2/PTGS2↓, PGE2↓, MMP9↓, MMP2↓, MMP9↓, TIMP2↓, Vim↓, COL1↓, E-cadherin↑, MDR1↓, AP-1↓, ChemoSen↑, chemoP↑, RadioS↑, TumAuto↑,
9021- Phyco,    C‑Phycocyanin induces apoptosis in oral squamous cell carcinoma KB cells via modulation of key molecular pathways
- in-vitro, Oral, KB
tumCV↓, selectivity↑, DNAdam↑, ChrCon↑, Apoptosis↑, NA↑, BAX↑, Bcl-2↓, Akt↓, PTEN↑, ERK↑,
9020- Phyco,    C-phycocyanin: a natural product with radiosensitizing property for enhancement of colon cancer radiation therapy efficacy through inhibition of COX-2 expression
- vitro+vivo, Colon, CT26 - in-vitro, CRC, DLD1 - in-vitro, CRC, HT-29 - in-vitro, Nor, CRL-1831
RadioS↑, Ki-67↓, Dose?,
9019- Phyco,    Phycocyanin-mediated apoptosis in AK-5 tumor cells involves down-regulation of Bcl-2 and generation of ROS
- in-vitro, sarcoma, AK-5
Apoptosis↑, Casp3↑, ROS↑, eff↓,
9017- Phyco,    Molecular mechanism of anti-cancer activity of phycocyanin in triple-negative breast cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7
eff↑, TumCP↓, Tumccf↓, TumCCA↑, cycE/CCNE↓, CDK2↓, P21↑, Apoptosis↑, γH2AX↑, Bax:Bcl2↑, Cyt‑c↑, Casp9↑, TumCMig↓, TumCA↑, angioG↓, COX2/PTGS2↓, PGE2↓, MAPK↓, toxicity↓,
9016- Phyco,    Phycocyanin Inhibits Tumorigenic Potential of Pancreatic Cancer Cells: Role of Apoptosis and Autophagy
- vitro+vivo, PC, PANC1 - in-vitro, PC, Capan1 - in-vitro, Liver, HepG2 - in-vitro, Lung, H460 - in-vitro, Pca, DU145
TumCP↓, TumCCA↑, Beclin-1/ATG6↑, p38↑, JNK↑, ERK↓, PI3K↓, Akt↓, mTOR↓, selectivity↑, Dose↝, toxicity↓, TumW↓, TumVol↓, TumAuto↑,
9015- Phyco,    Phycocyanin Exerts Anti-Proliferative Effects through Down-Regulating TIRAP/NF-κB Activity in Human Non-Small Cell Lung Cancer Cells
- in-vitro, Lung, H1975 - in-vitro, Lung, H1650 - in-vitro, Lung, LTEP-a2
Apoptosis↑, TumCG↓, TIRAP↓, NF-kB↓, p‑IKKα↓, p‑p65↓,
9014- Phyco,    C-Phycocyanin Suppresses the In Vitro Proliferation and Migration of Non-Small-Cell Lung Cancer Cells through Reduction of RIPK1/NF-κB Activity
- in-vitro, Lung, H1650
tumCV↓, TumCP↓, Tumccf↓, TumCMig↓, Apoptosis↑, RIP1↓, NF-kB↓, Dose↝, MMP9↓,
9013- Phyco,    Phycocyanin: Biomedical Activities and Related Mechanisms of Action
- Review, Nor, NA
*antiOx↑, *Imm↑, *Inflam↓, *AntiTum↑, *neuroP↑, *hepatoP↑, *cardioP↑,
9012- Phyco,    Phycocyanin from Arthrospira platensis as Potential Anti-Cancer Drug: Review of In Vitro and In Vivo Studies
- Review, Var, NA
*Ingr↝, *antiOx↑, *Inflam↓, Imm↑, AntiCan↑, *toxicity↓, *Dose↝, *GutMicro↑, *IBI↑, Apoptosis↑, TumCCA↑, DNArepair↓, ROS↑, Cyt‑c↑, BAX↑, cl‑PARP1↑, CellShr↑, TumCMig↓, COX2/PTGS2↓, E-cadherin↑, MMP2↓, MMP9↓, HIF-1↓, angioG↓, MCP1/CCL2↓, MIP-1β↑, Ca+2↑, Cal9↑, Wnt↓, β-catenin/ZEB1↓, PPARα↑, PPARγ↑, eff↝, Half-Life↓, Synergy↑, ChemoSen↑, chemoP↑, EMT↓, N-cadherin↓, E-cadherin↑, TumCMig↓, TumCI↓, selectivity↑,

Showing Research Papers: 1 to 21 of 21

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 21

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↑, 1,   ROS↓, 1,   ROS↑, 7,   SOD2↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mtDam?, 1,   mtDam↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 9,   Bak↑, 1,   BAX↑, 3,   Bax:Bcl2↑, 2,   Bcl-2↓, 2,   Casp↑, 1,   Casp3↑, 2,   cl‑Casp3↑, 1,   Casp9↑, 2,   CellShr↑, 1,   Cyt‑c↑, 4,   Fas?, 1,   p38↑, 1,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 3,   ERK↓, 1,   ERK↑, 2,   p‑IKKα↓, 1,   JAK3↓, 1,   JNK↑, 1,   MAPK↓, 1,   mTOR↓, 1,   PI3K↓, 1,   PTEN↑, 2,   RIP1↓, 1,   STAT3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 5,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 3,   DNArepair↓, 1,   P53↑, 1,   cl‑PARP↑, 1,   cl‑PARP1↑, 2,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 2,   ChrCon↑, 2,   cycE/CCNE↓, 2,   Ki-67↓, 1,   P21↑, 2,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Ki-67↓, 1,   TumCG↓, 2,   TumCP↓, 4,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AP-1↓, 1,   Ca+2↑, 1,   Cal9↑, 1,   COL1↓, 1,   E-cadherin↑, 3,   EMT↓, 3,   MMP2↓, 2,   MMP9↓, 4,   N-cadherin↓, 1,   TIMP2↓, 1,   TumCA↑, 1,   TumCI↓, 1,   TumCMig↓, 4,   Vim↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   HIF-1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD59↑, 1,   COX2/PTGS2↓, 4,   IFN-γ↓, 1,   IL1β↓, 1,   IL2↓, 1,   IL4↑, 1,   Imm↑, 1,   MCP1/CCL2↓, 1,   MIP-1β↑, 1,   NF-kB↓, 2,   p‑p65↓, 1,   PGE2↓, 2,   TIRAP↓, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

PPARα↑, 1,   PPARγ↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 2,   ChemoSen↑, 3,   Dose?, 1,   Dose↝, 4,   eff↓, 1,   eff↑, 1,   eff↝, 1,   Half-Life↓, 1,   MDR1↓, 1,   RadioS↑, 2,   selectivity↑, 5,   Synergy↑, 5,  

Clinical Biomarkers(tgid=22) ⓘ

Tumccf↓, 3,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   chemoP↑, 2,   hepatoP↑, 1,   toxicity↓, 2,   TumVol↓, 1,   TumW↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 108

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 3,   MPO↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

TXA2↓, 1,  

Barriers & Transport(tgid=15) ⓘ

IBI↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,   Imm↑, 2,   Inflam↓, 5,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 2,   Dose↝, 2,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   cardioP↑, 1,   hepatoP↑, 3,   neuroP↑, 1,   Pain↓, 1,   RenoP↑, 1,   toxicity↓, 3,  

Infection & Microbiome(tgid=24) ⓘ

GutMicro↑, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 2,  
Total Targets: 28

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:509  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page